“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ...
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the atezobladderpreserve phase II trial ...
Surgical Theater, the leader in surgical XR visualization, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for SyncAR® Spine, the next-generation release of its spine platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback